CR10822A - Formulacion en polvo del valganciclovir - Google Patents

Formulacion en polvo del valganciclovir

Info

Publication number
CR10822A
CR10822A CR10822A CR10822A CR10822A CR 10822 A CR10822 A CR 10822A CR 10822 A CR10822 A CR 10822A CR 10822 A CR10822 A CR 10822A CR 10822 A CR10822 A CR 10822A
Authority
CR
Costa Rica
Prior art keywords
powder formulation
dosage forms
valganciclovir
valganciclovir powder
cytomegalovirus
Prior art date
Application number
CR10822A
Other languages
English (en)
Inventor
Maria Oksana Bachynsky
Martin Horward Infeld
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39410167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10822(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR10822A publication Critical patent/CR10822A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invencion proporciona nuevas formas farmaceuticas solidas de dosificacion de valganciclovir clorhidrato para la administracion oral, despues de haberse constituido en agua. Estas nuevas formas farmaceuticas de dosificacion son utiles para el tratamiento o control de virus, tales como el virus herpes simplex y el citomegalovirus.
CR10822A 2006-12-13 2009-05-21 Formulacion en polvo del valganciclovir CR10822A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87463406P 2006-12-13 2006-12-13

Publications (1)

Publication Number Publication Date
CR10822A true CR10822A (es) 2009-06-25

Family

ID=39410167

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10822A CR10822A (es) 2006-12-13 2009-05-21 Formulacion en polvo del valganciclovir

Country Status (31)

Country Link
US (6) US20080146591A1 (es)
EP (1) EP2101733B1 (es)
JP (1) JP5111517B2 (es)
KR (1) KR101116553B1 (es)
CN (1) CN101541310B (es)
AR (1) AR065541A1 (es)
AU (1) AU2007332640B2 (es)
BR (1) BRPI0720118B8 (es)
CA (1) CA2671470C (es)
CL (1) CL2007003564A1 (es)
CO (1) CO6220902A2 (es)
CR (1) CR10822A (es)
DK (1) DK2101733T3 (es)
ES (1) ES2391912T3 (es)
HR (1) HRP20121033T1 (es)
IL (1) IL198854A (es)
MA (1) MA31280B1 (es)
MX (1) MX2009005921A (es)
MY (1) MY152540A (es)
NO (1) NO339838B1 (es)
NZ (1) NZ577179A (es)
PE (1) PE20081578A1 (es)
PL (1) PL2101733T3 (es)
PT (1) PT2101733E (es)
RS (1) RS52457B (es)
RU (1) RU2440118C2 (es)
SI (1) SI2101733T1 (es)
TW (1) TWI341730B (es)
UA (1) UA93599C2 (es)
WO (1) WO2008071573A2 (es)
ZA (1) ZA200903840B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111739A2 (en) * 2008-03-07 2009-09-11 Exley Ray W Treatment of herpes virus related diseases
CN102048677B (zh) * 2009-11-09 2014-03-05 杭州赛利药物研究所有限公司 一种盐酸缬更昔洛韦固体制剂及其制备方法
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
ES2621257T3 (es) * 2012-04-20 2017-07-03 Annji Pharmaceutical Co., Ltd. Ésteres de ciclopropanocarboxilato de análogos de purinas
RU2015132902A (ru) 2013-01-07 2017-02-09 Сам-А Фарм. Ко., Лтд. Новый быстрорастворимый состав гранул с улучшенной растворимостью
ES2629103T3 (es) * 2013-08-02 2017-08-07 Ali Raif Ilaç Sanayi Ve Ticaret Anonim Sirketi Formulación en polvo de valganciclovir
CN104055746B (zh) * 2014-07-12 2017-06-30 河北仁合益康药业有限公司 一种盐酸缬更昔洛韦包衣片剂组合物
RU2720805C1 (ru) * 2019-05-22 2020-05-13 Общество с ограниченной ответственностью "Трейдсервис" Фармацевтическая композиция валганцикловира
EP3976198A4 (en) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS
CN110613718A (zh) * 2019-09-19 2019-12-27 湖北科益药业股份有限公司 一种缬更昔洛韦组合物
CN110934823B (zh) * 2019-12-27 2022-03-01 湖北康源药业有限公司 一种盐酸缬更昔洛韦口服溶液及制备方法
WO2021161317A1 (en) * 2020-02-12 2021-08-19 Cts Chemical Industries Ltd. Stable pharmaceutical compositions comprising valgancyclovir and uses thereof
CN114028347B (zh) * 2021-11-30 2023-05-12 海南皇隆制药股份有限公司 注射用帕瑞昔布钠及其制备方法
CN115569113B (zh) * 2022-09-19 2023-11-10 江苏汉晨药业有限公司 一种盐酸缬更昔洛韦口服溶液

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880002139B1 (ko) 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5840890A (en) 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
EP1017372A4 (en) * 1997-10-03 2006-05-24 Smithkline Beecham Corp SOLID GALENIC FORMS WITH CONTROLLED LITHIUM CARBONATE RELEASE
US6221917B1 (en) * 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2244097A1 (en) * 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US20020143058A1 (en) * 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition
EP1459739B1 (en) * 2003-03-19 2008-01-02 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Non-hygroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids
WO2005021549A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Amorphous valganciclovir hydrochloride
WO2005087198A1 (en) * 2004-03-10 2005-09-22 Ranbaxy Laboratories Limited Processes for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride
CA2619035A1 (en) 2005-08-22 2007-03-01 Novartis Ag Pharmaceutical compositions

Also Published As

Publication number Publication date
AR065541A1 (es) 2009-06-17
IL198854A0 (en) 2010-02-17
HRP20121033T1 (hr) 2013-01-31
JP5111517B2 (ja) 2013-01-09
CN101541310B (zh) 2012-11-07
MX2009005921A (es) 2009-06-17
NZ577179A (en) 2011-12-22
DK2101733T3 (da) 2013-02-04
RS52457B (en) 2013-02-28
KR101116553B1 (ko) 2012-03-13
NO339838B1 (no) 2017-02-06
CO6220902A2 (es) 2010-11-19
EP2101733B1 (en) 2012-09-26
BRPI0720118B8 (pt) 2021-05-25
SI2101733T1 (sl) 2012-12-31
TWI341730B (en) 2011-05-11
CL2007003564A1 (es) 2008-07-18
AU2007332640A1 (en) 2008-06-19
WO2008071573A2 (en) 2008-06-19
MA31280B1 (fr) 2010-04-01
AU2007332640B2 (en) 2011-04-07
RU2440118C2 (ru) 2012-01-20
PL2101733T3 (pl) 2013-02-28
BRPI0720118A2 (pt) 2014-01-14
US20180153998A1 (en) 2018-06-07
PE20081578A1 (es) 2008-11-12
US9642911B2 (en) 2017-05-09
BRPI0720118B1 (pt) 2020-11-17
JP2010513237A (ja) 2010-04-30
TW200840585A (en) 2008-10-16
IL198854A (en) 2014-06-30
US20190117775A1 (en) 2019-04-25
UA93599C2 (en) 2011-02-25
CA2671470C (en) 2012-05-01
US8889109B2 (en) 2014-11-18
PT2101733E (pt) 2012-10-30
MY152540A (en) 2014-10-15
US20170266286A1 (en) 2017-09-21
EP2101733A2 (en) 2009-09-23
WO2008071573A3 (en) 2008-11-27
US20150057296A1 (en) 2015-02-26
NO20092254L (no) 2009-07-09
CN101541310A (zh) 2009-09-23
RU2009126616A (ru) 2011-01-20
ZA200903840B (en) 2010-03-31
US11185588B2 (en) 2021-11-30
ES2391912T3 (es) 2012-12-03
CA2671470A1 (en) 2008-06-19
US20080146591A1 (en) 2008-06-19
KR20090086469A (ko) 2009-08-12
US20130150382A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
CR10822A (es) Formulacion en polvo del valganciclovir
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12015502780B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
BR112015018168A2 (pt) inibidores de rock suaves
BR112015018087A8 (pt) composto, composição farmacêutica e uso
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
CL2015001374A1 (es) Compuestos derivados de 2-(metilamino)-n-(2-oxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3il)propanamida; composicion farmaceutica; y su uso en el tratamiento terapeutico o profilactico del cancer.
IL218277B (en) Tetracycline compounds, pharmaceutical preparations containing them and their use for the preparation of medicines for the treatment and prevention of infection
WO2012030914A8 (en) 4-azolylaminoquinazoline derivatives and methods of use thereof
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine